

# GLOBAL WHOLEHEALTH PARTNERS CORP

## **FORM 8-K** (Current report filing)

Filed 06/16/21 for the Period Ending 06/04/21

Address	1402 N EL CAMINO REAL SAN CLEMENTE, CA, 92672
Telephone	(714) 392-4112
CIK	0001598308
Symbol	GWHP
SIC Code	2835 - In Vitro and In Vivo Diagnostic Substances
Industry	Healthcare Facilities & Services
Sector	Healthcare
Fiscal Year	06/30

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2021

**GLOBAL WHOLEHEALTH PARTNERS CORPORATION**  
(Exact name of registrant as specified in its charter)

Nevada  
(State or other jurisdiction  
of incorporation)

000-56035  
(Commission File Number)

46-2316220  
(IRS Employer  
Identification No.)

1402 N El Camino Real  
San Clemente, CA  
(Address of Principal Executive Offices)

92672  
(Zip Code)

Registrant's telephone number, including area code (714) 392-9752

N/A  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Section 8 - Other Events**

**Item 8.01 Other Events.**

Effective June 4, 2021, Global Wholehealth Partners Corporation (the “Company”) was granted the rights from Nunzia Pharmaceutical Inc. (“Nunzia”) to distribute and sell the Pfizer-BioNTech COVID-19 Vaccine (“Vaccine”). The Company will serve as a broker for Nunzia and follow the same sales order processing as used by Nunzia in connection with the distribution and sale of the Vaccine.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**GLOBAL WHOLEHEALTH PARTNERS CORPORATION**  
(Registrant)

Date: June 16, 2021

By: /s/ Charles Strongo  
Charles Strongo  
Chief Executive Officer